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Introduction: Genetic susceptibility to complex diseases has been intensively studied during the last decade, yet
only signals with small effect have been found leaving open the possibility that subgroups within complex traits
show stronger association signals. In rheumatoid arthritis (RA), autoantibody production serves as a helpful
discriminator in genetic studies and today anti-citrullinated cyclic peptide (anti-CCP) antibody positivity is employed
for diagnosis of disease. The HLA-DRB1 locus is known as the most important genetic contributor for the risk of RA,
but is not sufficient to drive autoimmunity and additional genetic and environmental factors are involved. Hence,
we addressed the association of previously discovered RA loci with disease-specific autoantibody responses in RA
patients stratified by HLA-DRB1*04.
Methods: We investigated 2178 patients from three RA cohorts from Sweden and Spain for 41 genetic variants and
four autoantibodies, including the generic anti-CCP as well as specific responses towards citrullinated peptides from
vimentin, alpha-enolase and type II collagen.
Results: Our data demonstrated different genetic associations of autoantibody-positive disease subgroups in
relation to the presence of DRB1*04. Two specific subgroups of autoantibody-positive RA were identified. The SNP
in PTPN22 was associated with presence of anti-citrullinated enolase peptide antibodies in carriers of HLA-DRB1*04
(Cochran-Mantel-Haenszel test P = 0.0001, Pcorrected <0.05), whereas SNPs in CDK6 and PADI4 were associated with
anti-CCP status in DRB1*04 negative patients (Cochran-Mantel-Haenszel test P = 0.0004, Pcorrected <0.05 for
both markers). Additionally we see allelic correlation with autoantibody titers for PTPN22 SNP rs2476601 and
anti-citrullinated enolase peptide antibodies in carriers of HLA-DRB1*04 (Mann Whitney test P = 0.02) and between
CDK6 SNP rs42041 and anti-CCP in non-carriers of HLA-DRB1*04 (Mann Whitney test P = 0.02).
Conclusion: These data point to alternative pathways for disease development in clinically similar RA subgroups
and suggest an approach for study of genetic complexity of disease with strong contribution of HLA.* Correspondence: leonid.padyukov@ki.se
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The study of complex diseases has revealed complicated
patterns of inheritance [1] in which involvement of mul-
tiple variants and environmental conditions, as well as
gene-gene and gene-environmental interactions, have
made the discovery of genetic causes for complex dis-
eases a challenging task. One main methodological ca-
veat is the definition of phenotypes. As clinical features
of complex diseases are heterogeneous, one cannot ex-
pect simple genetic patterns to explain such complex
heterogeneity. By stratifying for more homogeneous dis-
ease subgroups/phenotypes one may try to achieve
stronger association and better understanding of disease
mechanisms [2,3].
Rheumatoid arthritis (RA) is a common complex dis-
ease with incidence around 0.5 to 1.0% in different po-
pulations [4,5] and a steadily growing prevalence in
aging Western and Eastern societies. Due to implemen-
tation of several targeted treatments in combination with
immunosuppressive therapy the overall quality of life for
RA patients has dramatically improved and many pa-
tients may stay in remission for long periods of time [6].
However, current treatments mostly decelerate rather
than cure disease, while disease-driving mechanisms re-
main poorly understood [6,7]. Despite the discovery of
multiple genetic associations with RA, variants within
the HLA-DRB1 locus, (that is, HLA-DRB1*04 alleles), re-
main the most significant contributors to the risk of
autoantibody-positive RA [8–14].
Antibody responses against citrullinated epitopes of
vimentin, fibrinogen, type-II collagen, alpha-enolase rep-
resent specific features of RA [11,12,15,16]. Patients may
display antibodies to one or several of these modified
self-proteins. Most of these autoantibody specificities are
confined within, and could thus be recognized on testing
as anti-citrullinated cyclic peptide (CCP) antibodies
[11,12], which is a generic test recognizing most anti-
citrulinated peptide antibody (ACPAs). A strong asso-
ciation between the shared epitope (SE) HLA-DRB1
alleles, specifically for SE HLA-DRB1*04 alleles, and
development of both anti-CCP and anti-citrullinated
alpha-enolase peptide-1 (CEP-1) antibodies has been re-
ported [17]. Subsets of RA defined by other combina-
tions of antibodies to citrullinated autoantigens have
been shown to display very different degrees of asso-
ciation with the common HLA-DRB1 risk alleles that
constitute the group of shared epitope alleles [18,19].
These different profiles of ACPAs may reflect distinct bio-
logical and immunological courses that are determined by
genetic niches of susceptibility. Although it is clinically
challenging to differentiate these subgroups due to rather
similar symptoms, it is essential to dissect these in view of
diagnosis and treatment, and ultimately for the under-
standing of disease mechanisms and possible prevention.To find additional links between genetics and serology
of RA, which will allow for studies of the relation-
ship between genotypes and phenotypes, we employed
a large population-based study from Sweden, the
Epidemiological Investigation of Rheumatoid Arthritis
(EIRA) with incident cases of RA and two smaller co-
horts of cases with well-established/chronic RA. We
also considered known relative stability of anti-CCP
levels through the RA development [20,21]. Our hy-
pothesis is that a polymorphism outside the HLA-DRB1
locus may contribute and shape the development of cer-
tain serological subtypes of RA, which are otherwise
clinically indistinguishable. We found that contribution
of different non-HLA single nucleotide polymorphisms
(SNPs) associated with RA in the development of
distinct ACPAs does not overlap, and may define
distinct subgroups of disease with an SE-positive or an
SE-negative background.
Methods
Patients and healthy subjects
DNA and serum samples were collected from three in-
dependent cohorts from Sweden and Spain (Additional
file 1: Table S13); all experiments were performed in ac-
cordance with the Declaration of Helsinki and were ap-
proved by Stockholm Ethical Review board or Comite
Etico de Investigacion Clinica de Galicia and all subjects
gave informed consent. Serum and DNA samples were
stored at −80°C until use. This was a case-case study to
test the hypothesis of the contribution of different gen-
etic factors in the development of serologically deter-
mined subgroups of RA.
The cohorts included were: 1) For initial study we
analyzed a cohort of 1,362 patients with incident RA
(cohort 1) from a population-based case–control study
(EIRA) [9,22]. The details of the EIRA study have been
described previously [22]. Briefly, a case was defined as
a person in the study base who received a new diagnosis
of RA from a rheumatologist (within 1 year after the on-
set of symptoms in 85% of the cases) and fulfilled the
American College of Rheumatology 1987 criteria for the
classification of RA [23]. Cases were recruited from all
public and a majority of private rheumatology units in
the study area; 2) cohort 2 comprised 379 patients with
established RA, who all fulfilled the American College
of Rheumatology criteria [23] and were attending the
Rheumatology Clinic at the Karolinska University Hos-
pital, Stockholm, Sweden; 3) cohort 3 comprised 437
patients with established RA classified according to the
1987 American College of Rheumatology criteria and of
Spanish ancestry; DNA and serum samples from these
patients were obtained from a single hospital. Their
clinical characteristics have been already described in
full [24].
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Detection of IgG anti-CCP antibodies
ELISA Anti-CCP2 test (Immunoscan RA, Mark 2, Euro-
Diagnostica, Malmö, Sweden) was used to determine the
levels of anti-CCP IgG antibodies. Quantification of the
results and use of a cut-off value of 25 U/ml were ac-
cording to the manufacturer’s instructions.
Detection of IgG antibodies against citrullinated
alpha-enolase peptide-1 (CEP-1, citrullinated type-II collagen
(citC1III) and citrullinated vimentin (cit-vim)
ELISA for detection of IgG antibodies against CEP-1,




DNA was extracted from ethylenediaminetetraacetic acid
(EDTA)-treated blood by the salting-out method [25].
Genotyping for HLA-DRB1 allotypes was conducted using
the sequence-specific primer-PCR method (DR low-
resolution kit; Olerup SSP, Saltsjöbaden, Sweden) as pre-
viously described [26]. DRB1*04- and DRB1*01-positive
patients were further subtyped by Olerup SSP DRB1*04
(Olerup SSP) subtyping kits, respectively [27,28]. In repli-
cation cohort 3, HLA-DBR1 alleles were genotyped by a
sequencing-based typing method using the AlleleSEQR
HLA-DRB1 Typing kit (Abbott Diagnostics, Abbott Park,
Germany), which includes bidirectional sequencing of the
second exon of DRB1. Ambiguous samples were additionally
sequenced with group-specific primers (AlleleSEQR HLA-
DRB1 GSSP, Abbott Diagnostics, Abbott Park, Germany).
Genotyping for RA-predisposing allelic variants
The 41 SNPs in the first phase of this study were se-
lected from previous studies of genetic risk factors for
RA; references for each SNP are presented in Additional
file 1: Table S14. These 41 SNPs were studied in the two
first cohorts of patients. Genotypes corresponding to the
EIRA cohort were retrieved from a genome-wide asso-
ciation study (GWAS) (26 SNPs) [29], from dense map-
ping of the HLA region (4 SNPs) [30] or from additional
genotyping (11 SNPs) that was performed by TaqMan al-
lelic discrimination assay (Applied Biosystems, Foster
City, CA, USA). Genotyping of cohort-2 was performed
using a 64-OpenArray platform (Applied Biosystems)
with the chip-based TaqMan genotyping technology.
Genotyping was performed according to manufacturer’s
instructions, and genotype calls were made using Auto-
Caller (Applied Biosystems). All SNPs that were analyzed
in this study are listed in Additional file 1: Table S14.
With the results of the two first cohorts we selected
12 SNPs for further analysis. The criteria of selection
were either a P-value <0.01 for association of the SNPwith a specific subgroup of autoantibody-positive pa-
tients in any of the two cohorts, or to show the same
direction of association and a P-value <0.2 in the two co-
horts. Genotyping for the 12 selected SNPs in cohort 3
(Spanish patients) was performed by PCR amplification
followed by single-base extension with the SNaPshot
Multiplex Kit (Applied Biosystems). Details of the pro-
tocol are available by the authors upon request. SNP
rs2476601 was genotyped with a Taqman SNP geno-
typing assay (Applied Biosystems, Carlsbad, CA, USA).Statistical analyses
We performed analyses either for the whole patient co-
hort, or for separate HLA-DRB1*04-positive patients and
HLA-DRB1*04-negative patients and further calculated
the odds ratios (OR) and 95% CI for the association with
anti-CCP and for three ACPA specificities. A dominant
genetic model or carrier model that assess the effect of
the presence of the risk allele, irrespective of the pre-
sence of one or two copies, was used for all analyses to
avoid too few counts of some patient subgroups. The
OR were calculated by median-unbiased estimation and
exact CI using the mid-P method [31] with patients
without the specific type of antibody as the reference
group.
The three cohorts were jointly analyzed (citC1III data
were only available for two cohorts) using the Cochran-
Mantel-Haenszel (CMH) test. An adjusted P-value of
0.05 after Bonferroni correction for multiple testing was
considered statistically significant in the meta-analysis.
Homogeneity between cohorts was tested by Tarone's
test. As we detected no significant heterogeneity bet-
ween cohorts a CMH fixed-effect model was fitted using
the restricted maximum-likelihood estimator. The metafor
R package was used for these analyses [32]. Antibody
levels and disease activity score in 28 joints (DAS28) were
compared by the Mann–Whitney test.Results
We determined the associations between genotypes and
phenotypes by performing a three-step analysis that is
represented in the analytical workflow chart in Figure 1.
At the first step, by analysis of cohort 1 and replication
in cohort 2, we selected 12 SNPs for further replication.
In a second step we validated the results in an independ-
ent cohort (cohort 3) and in the third step we estimated
OR for RA with certain serologic profiles, based on data
from all three cohorts, by meta-analysis. Our main goal
was to detect possible associations of non-DRB1 SNPs
with autoantibody-defined subgroups in relation to pre-
sence/absence of HLA-DRB1*04 alleles. However, we
also performed analysis for the whole group of patients
without this stratification.
Figure 1 Visual description of the analysis. SNP, single nucleotide polymorphism.
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Cohort 1 comprised 1,362 RA patients from the Swedish
EIRA study: 70% of the patients were positive for anti-
CCP antibodies, whereas defined ACPA fine specificities
were less frequent; 50% of the patients were positive for
anti-CEP-1 and 42% were positive for anti-cit-Vim and
for anti-citC1III antibodies (Additional file 1: Table S13).
We performed a case-case association study to test the
hypothesis of different genetic backgrounds between RA
subgroups identified by autoantibody specificity. Mul-
tiple SNPs were associated in the whole cohort or after
stratification by the major SE allele, HLA-DRB1*04, but
only few passed conservative corrections for multiple
testing (P ≤0.0004, Additional file 1: Tables S1-S4),
namely: SNP rs6457617 (HLA-DQB1 gene) for several
specificities, for the whole cohort and also after stratifica-
tion for HLA-DRB1*04, and rs2476601 (PTPN22 gene) for
the HLA-DRB1*04-positive RA group with anti-CEP-1
autoantibody.
With the goal to gain better statistical power and to
validate the associations identified, we performed ana-
lysis in cohort 2, an independent cohort of 379 Swedish
RA patients with established disease (Additional file 1:
Table S13). Most patients in this cohort were positive
for anti-CCP (73%) and for anti-citVim (58%). The other
two ACPAs were less frequent (46% for anti-CEP-1 and
38% for anti-citC1III). Again, although multiple SNPs
demonstrated a moderate trend towards association,
very few passed correction for multiple comparisons
(Additional file 1: Tables S5-S8). Therefore, we choose to
select the best candidate SNPs from association studies
in cohorts 1 and 2 for further validation. Two criteria
were used for selection, either a P-value <0.01 in any of
the two cohorts, or a change in the same direction with
P <0.2 in the two cohorts for the same comparison. This
procedure generated a list of 12 SNPs that were used atthe next step. Extracted data for association with these
SNPs from analyses of cohorts 1 and 2 are presented in
Table 1.
Association study in cohort 3
The 12 SNPs were genotyped in an independent collec-
tion of patients of Spanish ancestry, who had established
RA (n = 437). They showed a similar fraction of anti-
CCP positivity, but a lower frequency of the ACPAs
(Additional file 1: Table S13). The analysis revealed
moderate levels of association for SNPs from PTPN22,
PADI4, CDK6 and MICA in some disease subgroups
(Additional file 1: Tables S9-S11). Importantly, the di-
rection of associations followed the same pattern as in
cohorts 1 and 2.
Meta-analysis of the three cohorts
Following examination for heterogeneity, a fixed-effect
meta-analysis was conducted for the association of these
SNPs with anti-citrulline immunity in RA using data
available from the three cohorts; Table 2 and Figure 2
provide summarized results, which were Bonferroni-
corrected for the number of tests done. Additional file 1:
Table S12 provides the full disclosure of the analysis.
The results following stratification into carriers of HLA-
DRB1*04 and non-carriers of HLA-DRB1*04 showed asso-
ciations of the SNP in PTPN22 with antibodies to CEP-1
in the HLA-DRB1*04-positive group (adjusted P-value
0.007), and of two SNPs, in PADI4 and in CDK6, with
anti-CCP response in the HLA-DRB1*04-negative group
(adjusted p-value 0.038 and 0.034, respectively). In
addition, two SNPs showed a trend to association with
P-value <0.1 in the non-carriers of HLA-DRB1*04: CDK6
and PRKCQ with anti-citVim and anti-CEP-1 respectively
(Table 2, Additional file 1: Table S12, and Figure 2). These
data additionally endorse the association of RA subgroups
Table 1 Selected associations found in cohorts 1 and 2
Gene rs number Chromosome Position Cohort 1
P-value




Cohort 2 odds ratio
(95% CI)
Anti-CCP
Anti-CCP - all patients
PTPN22 rs2476601 1 114179091 0.119 1.235 (0.948, 1.617) 0.104 1.519 (0.920, 2.569)
MICA rs2523451 6 31477130 0.062 1.382 (0.984, 1.938) 0.035 1.707 (1.039, 2.795)
HLA-DQB1 rs6457617 6 32771829 2.22 × 10−16 4.232 (2.998, 6.008) 0.131 2.028 (0.803, 4.911)
CDK6 rs42041 7 92084680 0.017 1.368 (1.056, 1.777) 0.162 1.404 (0.874, 2.285)
Anti-CCP-– HLA-DRB1*04 patients
PTPN22 rs2476601 1 114179091 0.018 1.67 (1.090, 2.628) 0.19 1.751 (0.765, 4.415)
Anti-CCP - Non-HLA-DRB1*04 patients
PADI4 rs2240340 1 17535226 0.012 1.718 (1.128, 2.625) 0.15 1.627 (0.838, 3.176)
CDK6 rs42041 7 92084680 0.001 1.831 (1.265, 2.660) 0.055 1.909 (0.987, 3.772)
Citrullinated-vimentin
Citrullinated-vimentin - all patients
PTPN22 rs2476601 1 114179091 0.048 1.272 (1.002, 1.614) 0.021 1.691 (1.083, 2.667)
MICA rs2523451 6 31477130 0.005 1.595 (1.151, 2.221) 0.009 1.818 (1.162, 2.851)
HLA-DQB1 rs6457617 6 32771829 2.36 × 10−10 3.417 (2.285, 5.266) 0.001 4.948 (1.890, 15.652)
HLA-DPB1 rs2064476 6 33181300 0.19 1.636 (0.787, 3.594) 0.028 3.228 (1.132, 10.682)
TRAF1 rs3761847 9 122730060 0.088 1.254 (0.967, 1.631) 0.171 1.406 (0.863, 2.289)
Citrullinated-vimentin - HLA-DRB1*04 patients
PTPN22 rs2476601 1 114179091 0.022 1.437 (1.054, 1.967) 0.04 1.912 (1.029, 3.672)
MICA rs2523451 6 31477130 0.085 1.495 (0.945, 2.362) 0.133 1.639 (0.858, 3.106)
Citrullinated-vimentin - non-HLA-DRB1*04 patients
HLA-DQB1 rs6457617 6 32771829 0.161 1.387 (0.880, 2.233) 0.042 2.814 (1.034, 9.151)
CEP-1
CEP-1- all patients
PTPN22 rs2476601 1 114179091 0.016 1.339 (1.055, 1.702) 0.078 1.475 (0.957, 2.279)
HLA-DQB1 rs6457617 6 32771829 5.11 × 10−11 3.213 (2.242, 4.676) 0.166 1.896 (0.772, 5.144)
PRKCQ rs4750316 10 6433266 0.133 1.204 (0.945, 1.534) 0.004 1.86 (1.220, 2.849)
HTR2A rs1328674 13 46339708 0.187 1.33 (0.871, 2.051) 0.115 1.924 (0.854, 4.546)
CEP-1 - HLA-DRB1*04 patients
CIITA rs6416647 16 10873098 0.011 1.525 (1.099, 2.121) 0.194 1.431 (0.833, 2.468)
CEP-1 - non-HLA-DRB1*04 patients
HLA-DQB1 rs2064476 6 33181300 0.002 1.894 (1.268, 2.865) 0.155 3.8 (0.656, 97.488)
PRKCQ rs4750316 10 6433266 0.106 1.379 (0.934, 2.035) 0.003 2.919 (1.446, 5.965)
CitC1III
CitC1III - all patients
MMEL1 rs3890745 1 2543484 0.158 1.319 (0.899, 1.959) 0.122 1.883 (0.850, 4.634)
CDK6 rs42041 7 92084680 0.166 1.181 (0.933, 1.495) 0.044 1.549 (1.012, 2.372)
CitC1 - HLA-DRB1*04 patients
TNFAIP3 rs6920220 6 138048197 0.067 1.796 (0.960, 3.504) 0.052 3.254 (0.991, 15.257)
CitC1III - non-HLA-DRB1*04 patients
CDK6 rs42041 7 92084680 0.038 1.502 (1.023, 2.210) 0.051 1.99 (0.997, 3.988)
P-values in bold represent the most significant associations with values <0.05 for both cohorts.
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Table 2 Association of genetic markers with serological subgroups of rheumatoid arthritis: meta-analysis summary
Anti-CPP
HLA-DRB1*04-positive group HLA-DRB1*04-negative group
Reference sequence for single
nucleotide polymorphism (SNP)
Gene Uncorrected P-value Corrected P-value Uncorrected P-value Corrected P-value
rs3890745 MMEL1 0.1222 1.000 0.2888 1.000
rs2240340 PADI4 0.3381 1.000 0.0004 0.038
rs2476601 PTPN22 0.0142 1.000 0.2356 1.000
rs2523451 MICA 0.2676 1.000 0.8643 1.000
rs6457617 HLA-DQ 0.3272 1.000 0.0024 0.228
rs2064476 HLA.DPB2 0.9817 1.000 0.0604 1.000
rs6920220 TNFAIP3 0.5221 1.000 0.5579 1.000
rs42041 CDK6 0.5768 1.000 0.0004 0.034
rs3761847 TRAF1 0.3759 1.000 0.5073 1.000
rs4750316 PRKCQ 0.0225 1.000 0.9611 1.000
rs1328674 HTR2A 0.1093 1.000 0.2167 1.000
rs6416647 CIITA 0.4205 1.000 0.8600 1.000
anti-cit-Vimentin
HLA-DRB1*04-positive group HLA-DRB1*04-negative group
Reference sequence for SNP Gene Uncorrected P-value Corrected P-value Uncorrected P-value Corrected P-value
rs3890745 MMEL1 0.1174 1.000 0.8047 1.000
rs2240340 PADI4 0.1918 1.000 0.2833 1.000
rs2476601 PTPN22 0.0111 1.000 0.9087 1.000
rs2523451 MICA 0.0394 1.000 0.0713 1.000
rs6457617 HLA-DQ 0.6668 1.000 0.0727 1.000
rs2064476 HLA.DPB2 0.0172 1.000 0.1853 1.000
rs6920220 TNFAIP3 0.0601 1.000 0.9923 1.000
rs42041 CDK6 0.8207 1.000 0.0009 0.088
rs3761847 TRAF1 0.0877 1.000 0.2822 1.000
rs4750316 PRKCQ 0.8846 1.000 0.0231 1.000
rs1328674 HTR2A 0.0557 1.000 0.3165 1.000
rs6416647 CIITA 0.1542 1.000 0.3807 1.000
anti-CEP-1
HLA-DRB1*04-positive group HLA-DRB1*04-negative group
Reference sequence for SNP Gene Uncorrected P-value Corrected P-value Uncorrected P-value Corrected P-value
rs3890745 MMEL1 0.9475 1.000 0.0240 1.000
rs2240340 PADI4 0.6073 1.000 0.4651 1.000
rs2476601 PTPN22 0.0001 0.006 0.4364 1.000
rs2523451 MICA 0.1623 1.000 0.1834 1.000
rs6457617 HLA-DQ 0.0558 1.000 0.0028 0.267
rs2064476 HLA.DPB2 0.3083 1.000 0.6594 1.000
rs6920220 TNFAIP3 0.8999 1.000 0.5037 1.000
rs42041 CDK6 0.3235 1.000 0.0459 1.000
rs3761847 TRAF1 0.6790 1.000 0.2747 1.000
rs4750316 PRKCQ 0.5904 1.000 0.0007 0.070
rs1328674 HTR2A 0.0582 1.000 0.2357 1.000
rs6416647 CIITA 0.0089 0.852 0.8989 1.000
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Table 2 Association of genetic markers with serological subgroups of rheumatoid arthritis: meta-analysis summary
(Continued)
anti- CitC1III
HLA-DRB1*04-positive group HLA-DRB1*04-negative group
Reference sequence for SNP Gene Uncorrected P-value Corrected P-value Uncorrected P-value Corrected P-value
rs3890745 MMEL1 0.1310 1.000 0.2013 1.000
rs2240340 PADI4 0.5328 1.000 0.1821 1.000
rs2476601 PTPN22 0.2301 1.000 0.3068 1.000
rs2523451 MICA 0.3840 1.000 0.9666 1.000
rs6457617 HLA-DQ 0.4136 1.000 0.0021 0.201
rs2064476 HLA.DPB2 0.9029 1.000 0.9872 1.000
rs6920220 TNFAIP3 0.0148 1.000 0.6307 1.000
rs42041 CDK6 0.4844 1.000 0.0054 0.522
rs3761847 TRAF1 0.8086 1.000 0.3773 1.000
rs4750316 PRKCQ 0.5519 1.000 0.3662 1.000
rs1328674 HTR2A 0.6374 1.000 0.3458 1.000
rs6416647 CIITA 0.2613 1.000 0.7296 1.000
Odds ratios are presented in Figure 2; full details are presented in Additional file 1: Table S12. P-values in bold represent the most significant associations with
corrected values <0.10.
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relevant candidate for follow-up studies.
In the analyses without stratification according to
HLA-DRB1*04, the SNP assigned to MICA was associ-
ated with response to cit-Vim (adjusted P-value 0.008),
the PTPN22 SNP was associated with antibodies to
CEP-1 (adjusted P-value 0.012), and the HLA-DQB1
SNP was associated with the anti-citC1III antibodies
(adjusted P = 9 × 10−5) (Additional file 1: Table S12).
These findings suggest a relative independence of the as-
sociation with the MICA SNP from HLA-DRB1*04 as
the OR are very uniform in the two groups of patients
stratified by this allele (OR = 1.4 in the carriers and in
non-carriers). This independence was not present in the
association with the PTPN22 SNP that showed a stron-
ger significant association in the carriers of DRB1*04
than in the non-carriers (OR = 1.7 and 1.1, respectively).
Analysis of serological and clinical data
As our data showed that SNPs in PADI4, PTPN22 and
CDK6 together with HLA-DRB1*04 carrier status were
associated with the presence of some autoantibodies, we
tested if the genotypes were correlated with the titers of
these antibodies. We saw a coherent significant diffe-
rence for anti-CCP antibody levels between homozygous
CC patients and those carrying the G allele of rs42041
from CDK6 in cohort 1 and 2 for patients without
DRB1*04 alleles (P = 0.0193 and 0.0290 for cohorts 1 and
2, Additional file 2: Figure S1a). Similarly, patients having
the AA/AG variant of rs2476601 from PTPN22 had higher
levels of antibodies towards cit-Vim in cohort 1 and 2 butonly in patients with DRB1*04 alleles (P = 0.0238,
Additional file 2: Figure S1c).
To compare genetic subgroups defined by certain auto-
antibody specificity, HLA-DRB1*04 and non-HLA alleles
(PTPN22, PADI4 and CDK6), we analyzed data on disease
activity at baseline in cohort 1 measured by the DAS28,
but no differences were found (data not shown).
Discussion
In this study we have demonstrated that specificity of
autoantibody responses in seropositive RA is regulated
not only by HLA-DRB1*04, but also by at least three
additional non-HLA genetic variants: PADI4, PTPN22
and CDK6. Our data suggest that PTPN22 involvement
is restricted to HLA-DRB1*04 carriers, while associations
of PADI4 and CDK6 are restricted to the non-carriers,
and they also differ in autoantibody specificity. While
concordance of HLA-DRB1*04 and PTPN22 SNP in
anti-CEP-1 positive RA was demonstrated previously in
a single cohort [17,19], the involvement of genetic vari-
ants of PADI4 and CDK6 in risk of development of RA
subgroups only in the absence of HLA-DRB1*04 is a
new finding. We also have observed a difference in the
autoantibody titers corresponding with the previous as-
sociations, (Additional file 2: Figure S1) while no differ-
ence was found in relation to clinical activity of disease
at baseline measured by the DAS28.
Genetic and environmental factors are involved in the
etiology of complex diseases. In RA, such susceptibility
factors have been primarily found for ACPA-positive
disease [7,9,33]. Among RA-predisposing genes, the
Figure 2 Overview of the most significant associations in the study. The bars represent the odds ratio on the horizontal scale with the
99.999% CI for comparison between group of persons with and without autoantibody (distinguished by color of the bar) and carriers and
non-carriers of the major allele with separation to HLA-DRB1*04-positive and HLA-DRB1*04-negative. Results are presented for the final selection
of SNPs and meta-analysis of three cohorts (two cohorts for anti-CitC1). Indicated P-values are the values after Bonferroni correction. Full details
are presented in Additional file 1: Table S12.
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extensively studied, as it was the first identified and it
was also the strongest to date [27,34]. Association of the
shared epitope alleles of HLA-DRB1 with ACPA (anti-
CCP)-positive RA indicates probable mechanisms for
disease development. In this work, we further examined
the significance of other, mainly non-HLA variants, for
the development of different autoantibodies in a case-
case study. We investigated the effects of these genetic
variants alone or in combination with HLA-DRB1*04,
the most frequent SE alleles in European Caucasians, in
three independent RA cohorts. Although the selection of
SNPs was based on RA susceptibility studies our results
are not related to susceptibility by itself, because no
comparison with healthy individuals was done.Despite the fact that HLA-DRB1*04 alleles are strongly
associated with RA and anti-citrulline immunity, few stu-
dies have so far addressed the contribution of these allelic
variants to RA development via antigen presentation of
citrullinated peptides [35–38]. It is not clear why and how
HLA-DRB1*04-positive RA patients develop ACPAs with
different specificities towards non-overlapping epitopes. It
is therefore possible that the HLA-DR*04 alleles (mainly
*04:01) together with additional genes outside this region
work collectively to shape ACPA responses in RA. In this
study, we found three allelic variants outside HLA-DRB1
that associate with a particular type of autoantibody in
RA. These genetic differences may provide a plausible
explanation for the phenotypic heterogeneity of RA, for
example, differences in the autoantibody profile of RA
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of these variants to RA development remains to be
determined.
The PTPN22 gene (MIM ID*600716) encodes an 807
amino acid lymphoid tyrosine phosphatase of non-
receptor type (LYP). An SNP in this gene was found to be
associated with several autoimmune diseases [39]. This
SNP is a non-synonymous change of arginine for tryp-
tophan at position 620 of the protein. The biochemical
effect and the resulting disease risk of this SNP have been
very difficult to study and there is not yet consensus about
its functional consequences. It has been suggested that
this SNP determines a gain of function of the LYP phos-
phatase, but there other studies showing a loss of function
of LYP when analyzed together with the c-Src tyrosine
kinase [40]. Therefore, it is still unclear how the R620W
change might contribute to autoimmunity. In addition,
most studies of PTPN22 function refer to T cell function
either at the level of thymic selection or of mature T cell
activation, but B cells also express LYP and the removal of
autoreactive B cells is deficient in subjects bearing the risk
allele of PTPN22, making for alternative mechanisms of
disease risk [41].
The CDK6 gene (MIM ID* 603368) encodes a 326
amino acid serine/threonine-protein kinase, which is
ubiquitously expressed and involved in cell cycle control
and differentiation by promoting G1/S transition. A ge-
netic polymorphism at CDK6 was recently found to be
associated with RA [42] and with joint destruction du-
ring RA [43]. Interestingly, polymorphisms in this gene
are also associated with adult height [44] and with white
blood cells counts in some populations [45,46].
The PADI4 gene (MIM ID *605347) codes for peptidyl
arginine deiminase, type 4, which mediates citrullination
of different proteins, including histones. In histones, citrul-
lination affects methylation and this way PADI4 influences
gene expression [47]. PADI4 variants have previously been
observed to be associated with RA in the Japanese po-
pulation [48] and recently in European Caucasians [49].
Although the enzyme is directly involved in citrullination
of proteins, until now genetic association has not been
restricted to RA patients positive for autoantibodies to
citrullinated antigens [50].
There were three loci showing significant association
with particular autoantibodies in the analysis non-
stratified by HLA-DRB1*04. The associations between
the anti-citC1III antibodies and the HLA-DQB1 SNP and
between the anti-citVim antibodies and the SNP in
MICA could reflect linkage disequilibrium with the
shared epitope alleles of HLA-DRB1 because these SNPs
are in the HLA region. However, we cannot exclude an
effect of other variants in this region as has been shown
for RA susceptibility [13]. The third association, between
anti-CEP-1 antibodies and the PTPN22 SNP and anti-CEP-1 antibodies, although observed in the non-stratified
analysis was not independent of the presence of HLA-
DRB1*04. It was much stronger in the carriers of HLA-
DRB1*04 than in the non-carriers, as already discussed.
What are the possible mechanisms underlying the iden-
tified associations and how will our findings affect the un-
derstanding of, or the management of RA? It is clear that
HLA-DRB1*04, as well as other SE alleles, do not repre-
sent a single determinant for development of autoimmune
responses. We previously demonstrated the possibility
of gene-gene and gene-environment interactions in the
development of RA which suggested that smoking and
several non-HLA genes could serve as possible second de-
terminants for a break in tolerance to self antigens and
the development of RA. Two of the genes in our study,
CDK6 and PTPN22, are directly involved in signaling
pathways that are essential for immune cell function.
However, due to redundancy of these pathways we cannot
point to the specific type of cells that are involved in the
development of disease: it could be downstream mecha-
nisms with T helper cells as primer players, or upstream
mechanisms related to antigen presenting cells, B cells,
macrophages/monocytes or dendritic cells. As the com-
bination of HLA-DRB1*04 and variations from these genes
are unlikely to be sufficient for RA development, one
would expect a third determinant to be involved in this
interaction. Our findings warrant future studies of the de-
velopment of autoimmune responses in individuals at risk
of RA, with certain subphenotypes, based on serological
testing. It would guide both understanding of specific
mechanisms and probable treatment towards precision
medicine in contrast to current treatment based on rela-
tively non-specific immunosuppressive therapy (that is,
RA symptoms). Such studies may guide both understand-
ing of specific mechanisms and future development of
more specific therapies for patients from these different
subsets. One such option that may be discussed based on
our current observations in ACPA-negative RA patients is
to test the selective cyclin-dependent kinase 4/6 (CDK4/6)
inhibitor (Momilactone B) which is currently being inves-
tigated for treatment of colon cancer [51].
There are several strengths in our study. First, we
performed analysis in three independent cohorts of RA
patients. Second, we used cohorts from two different
countries, with different frequencies of autoantibodies,
and different types of RA. This variability between
sample collections is important for generalization of our
findings. Third, our final conclusions were based on the
Bonferroni correction and this is a very conservative ap-
proach when analyzing correlated variables, such as the
four autoantibodies in our study.
There are also some weaknesses in the current study:
1) as the phenotypes we have studied involved a combi-
nation of traits, they comprised relatively small numbers
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included in the study; 2) inclusion of incident cases
(EIRA) and established RA (cohorts 2 and 3) may have
decreased the power of our study to discover associa-
tions that are specific for a particular disease phase; 3)
we did not address the contribution of other SE alleles
beyond DRB1*04 in our study due to a relatively low fre-
quency of HLA-DRB1*01 and *10 in our cohorts; 4) it
also would be beneficial to address the influence of
smoking, but we did not have enough statistical power
for inclusion of an additional covariate in our analyses.
Conclusions
Autoimmune diseases display strong association with
HLA alleles, but a substantial number of non-HLA va-
riants are also associated at genome-wide level. Specific
subphenotype analyses of these associated loci have been
rare, and have usually not been stratified by HLA alleles.
Our study provides a prototype that could be useful for
other studies aiming to disentangle RA complexity. The
ongoing replications and extensions of such studies
should provide a basis for a molecular re-classification
of RA based on genetic and serological features, rather
than mainly on clinical data [52]. Specifically, our study
confirms the hypothesis that polymorphisms outside the
HLA-DRB1 locus contribute to the development of spe-
cific serological subphenotypes of RA, which may have
different mechanisms of disease development.
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